Article Text

Download PDFPDF

5PSQ-109 Haemoassist: a digital bridge between haemophilia patients and pharmacists
  1. N Blazquez-Ramos,
  2. JA Romero Garrido,
  3. C Bilbao Gómez-Martino,
  4. C Sobrino Jimenez,
  5. C Jimenez Nunez,
  6. ME Ibañez Ronco,
  7. L Carrasco Cuesta,
  8. S Mallon Gonzalez,
  9. VL Collada Sánchez,
  10. AB Arancon Pardo,
  11. A Herrero Ambrosio
  1. Hospital Universitario La Paz, Hospital Pharmacy, Madrid, Spain


Background and Importance Patients with severe haemophilia will need regular parenteral treatment throughout their lives to restore their haemostasis.

These patients reach a high degree of autonomy and their follow-up can be a challenge for healthcare professionals.

In 2020 our Pharmacy Service (PS) offered a mobile application (Haemoassist®) to 315 patients so that they could record their pharmacological administrations, specifying whether for prophylactic purposes or to treat active bleeding.

Aim and Objectives Compare app usage data obtained in 2022, with the data published in 2020, to know if we are achieving:

- Increase the number of patients using the app.

- Improve the quality of the data entered in the app.

Material and Methods

  • Count the number of patients who used the app in 2022.

  • We studied the degree of concordance between the adherence offered by the app (reported administered doses/prescribed doses) and that calculated from the PS (dispensed doses/prescribed doses).

  • Check whether all patients who, according to the data collected in the hospital’s medical record, had bled and were using the app, had reported these bleeds in the app.

Material and MethodsWe compared these 2022 data with those published in 2020.

Results 190 patients used the app on some occasion during 2022 compared to 169 patients in 2020.

In 2022, the median adherence achieved by the 190 patients, according to the app, was 8% and the Interquartile Range (IR):0–57% and according to the SF dispensations was 92% (IR: 77 -99%). The degree of concordance between the two calculation methods was 18%. In 2020, concordance was 9%.

Of the 190 patients using the app in 2022, according to the hospital’s medical records, 153 of them had a bleeding episode, but only 74 reported their bleeds in the app. The 48% of patients reported their bleeds in the app in 2022 versus 54% in 2020.

Conclusion and Relevance The number of patients using the app has been increasing. The quality of patient-reported data is slowly improving.

References and/or Acknowledgements 1. Nuria Blazquez-Ramos, Romero-Garrido José A, Luis Gonzalez Del Vall, Hortensia De la Corte-Rodriguez, Alicia Herrero-Ambrosio, Carlos Rodriguez-Merchan E. Development of a telematic pharmaceutical care app (Haemoassist) for multidisciplinary follow-up of patients with congenital coagulopathies. Expert Review of Hematology. 2023;16:3:213–226. DOI: 10.1080/17474086.2023.2162497

Conflict of Interest No conflict of interest.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.